^
    Apply
    Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) (NCT05061017)
    Phase 2
    Diwakar Davar
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    12/09/2021
    Primary completion :
    02/05/2024
    Completion :
    03/18/2024
    KRAS • BRAF • ALK • MET
    |
    KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • cyclophosphamide intravenous • pixatimod (PG545)